Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.39 |
| ▸ | FEN1 | P39748 | 4/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501577 | 0.91 | ALOX5AP (0.39) | SCN9APTGDR2ALOX5APFEN1DDR1 | |
| SCHEMBL17664612 | 0.89 | PTGS2 (0.38) | PTGDR2ALOX5APFEN1DDR1 | |
| SCHEMBL19501581 | 0.88 | ALOX5AP (0.37) | PTGDR2ALOX5APFEN1DDR1 | |
| SCHEMBL17664475 | 0.87 | ALOX5AP (0.37) | PTGDR2ALOX5APFEN1DDR1 | |
| SCHEMBL19501582 | 0.84 | PTGDR2 (0.35) | PTGDR2ALOX5APFEN1DDR1 | |
| SCHEMBL18908792 | 0.83 | LMNA (0.49) | PTGDR2ALOX5APFEN1DDR1LMNA | |
| SCHEMBL17664487 | 0.83 | PTGDR2 (0.35) | PTGDR2ALOX5APFEN1DDR1 | |
| SCHEMBL19501575 | 0.81 | ALOX5AP (0.41) | PTGDR2ALOX5APFEN1DDR1 | |
| SCHEMBL17664492 | 0.78 | FEN1 (0.46) | SCN9AALOX5APFEN1KDRMAPK14 | |
| SCHEMBL17664616 | 0.77 | SCN9A (0.36) | SCN9APTGDR2ALOX5APFEN1DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802930-B1 | Pyrimidinone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20170305896-A1 | PYRIMIDINONE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3202762-A1 | PYRIMIDINONE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2017-08-09 | — | — | EP | disclosed |
| WO-2017090654-A1 | PEST CONTROL COMPOSITION AND USE THEREOF | 住友化学株式会社 | 2017-06-01 | — | — | WO | disclosed |
| WO-2016052247-A1 | PYRIMIDINONE COMPOUND | 住友化学株式会社 | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305896-A1 | PYRIMIDINONE COMPOUND | C5, C3AR1, CCR3 | SCN9A 2811/4885PTGDR2 1449/4885ALOX5AP 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.